IP Library Granted Patent US 9,382,531
Granted Patent B2
US 9,382,531 · App. 14/058,959 · Granted Jul 5, 2016

Induction of hemogenic endothelium from pluripotent stem cells

Inventors: Igor Slukvin (Verona, WI); Irina Elcheva (Madison, WI)
Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
C12N15/00C12N5/0647C12N15/11C12N15/66C12N2501/60C12N2501/998C12N2506/02C12N2506/45C12N2740/16043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,382,531
App. No.
14/058,959
Granted
Jul 5, 2016
Kind
B2
Abstract

Described herein are methods and related compositions for inducing differentiation of human pluripotent stem cells (hPSCs) into hemogenic endothelium with pan-myeloid potential or restricted potential, by forced expression in the hPSCs of a combination of transcription factors as described herein.

Claims (8)

1. A method for generating human hemogenic endothelial cells with pan-myeloid potential, comprising:

(i) introducing into human pluripotent stem cells an exogenous ETV2 or ERG protein and an exogenous GATA1 protein; and (ii) culturing the human pluripotent stem cells following step (i) under culture conditions that support expansion of hematopoietic cells to obtain hemogenic endothelial cells that are VE-cadherin + , CD226 + , and CD73 − .

2. The method of claim 1 , further comprising culturing the hemogenic endothelial cells of step (ii) for an additional period of at least one to about four days to obtain CD43 + hematopoietic cells.

3. The method of claim 2 , wherein the additional culture period comprises co-culturing the hemogenic endothelial cells with OP9 stromal cells.

4. The method of claim 1 , wherein the culturing conditions of step (ii) comprise culturing in the presence of FGF2, SCF, and thrombopoietin.

5. The method of claim 1 , wherein the exogenous ETV2 or ERG protein and the exogenous GATA1 protein are present in the cells for at least two to about three days.

6. The method of claim 1 , wherein the introducing step (i) comprises transducing the human pluripotent stem cells with a recombinant expression virus comprising a nucleic acid encoding a ETV2 or ERG protein and a GATA1 protein, transfecting the human pluripotent stem cells with a double stranded DNA expression vector comprising a nucleic acid encoding a ETV2 or ERG protein and a GATA1 protein, transfecting the human pluripotent stem cells with a modified mRNA encoding a an ETV2 or ERG protein and a GATA1 protein, transfecting the human pluripotent stem cells with a ETV2 or ERG protein and a GATA1 protein, or a combination thereof.

7. The method of claim 1 , wherein the ETV2 protein, ERG protein, or GATA1 protein are from human, mouse, or rat.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2014
From: SLUKVIN, IGOR; ELCHEVA, IRINA
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 032074/0155 →
CONFIRMATORY LICENSE Recorded Oct 30, 2013
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031514/0966 →
Continuity (2)
Provisional Application 61716875 · Oct 22, 2012
Related Publication 20140234971A1 · Aug 21, 2014